This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Intuitive Surgical Inc. (ISRG): Today's Featured Health Care Loser

Intuitive Surgical ( ISRG) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day down 1.2%. By the end of trading, Intuitive Surgical fell $19.62 (-3.6%) to $531.77 on heavy volume. Throughout the day, 637,975 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 305,200 shares. The stock ranged in price between $527.44-$547.85 after having opened the day at $545.61 as compared to the previous trading day's close of $551.39. Other company's within the Health Care sector that declined today were: MAKO Surgical Corporation ( MAKO), down 43.1%, Rexahn Pharmaceuticals ( RNN), down 31%, Questcor Pharmaceuticals ( QCOR), down 21.8%, and Stereotaxis ( STXS), down 15.3%.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems for various surgical procedures, including urologic, gynecologic, cardiothoracic, general, and head and neck surgeries. Intuitive Surgical has a market cap of $21.89 billion and is part of the health services industry. The company has a P/E ratio of 41.7, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 19.1% year to date as of the close of trading on Monday. Currently there are five analysts that rate Intuitive Surgical a buy, no analysts rate it a sell, and eight rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.

On the positive front, Sunshine Heart ( SSH), up 37.8%, BioMimetic Therapeutics ( BMTI), up 23.6%, K-V Pharmaceutical Company ( KV.A), up 13.3%, and Hooper Holmes ( HH), up 12.1%, were all gainers within the health care sector with Hologic ( HOLX) being today's featured health care sector winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs